Abcam, ab316285, Anti-HCoV-229E Nucleocapsid protein antibody [abd210]

Size: 20µg / 100µg / 1mg
Human Recombinant Monoclonal NCAP antibody. Suitable for ICC/IF, I-ELISA and reacts with Transfected cell line - Human coronavirus 229E, Recombinant fragment - Human coronavirus 229E samples.
Key facts
Host species:Human,
Clonality:Monoclonal,
Clone number:abd210,
Isotype:IgG1,
Carrier free:No,
Reacts with:Human coronavirus 229E,
Applications:ICC/IF, I-ELISASee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:This antibody does not cross-react with recombinant Human coronavirus NL63 nucleocapsid, MERS-CoV nucleocapsid, SARS-CoV nucleocapsid, Human coronavirus OC43 nucleocapsid and Human coronavirus HKU1-Cov nucleocapsid.

Product details:
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The HCoV-229E Nucleocapsid protein also known as the N protein plays a mechanical role within the human coronavirus 229E (HCoV-229E). This protein has a mass of around 45 kDa and is expressed in the cytoplasm of infected host cells. Its primary function lies in binding to the viral RNA genome forming a ribonucleoprotein complex that protects the RNA and contributes to the stability of the viral genome. The HCoV-229E nucleocapsid protein is important for the correct assembly and packaging of the viral RNA into new virions.
Biological function summary
The N protein directly impacts viral replication and transcription. It forms part of a larger ribonucleoprotein complex that organizes the viral genome into a functional and protected structure. This complex interacts with other viral proteins to facilitate the replication process. The N protein also boosts the efficiency of the viral RdRp (RNA-dependent RNA polymerase) in transcribing the RNA genome ensuring that viral replication proceeds efficiently and effectively within host cells.
Pathways
The N protein integrates into the coronavirus replication-transcription complex. It coordinates with the viral RdRp and other non-structural proteins of the virus to ensure a streamlined replication process. This protein interacts with cellular pathways that include stress response and immune pathways potentially modulating host immune responses to benefit viral survival and replication. These interactions with host cell pathways may influence the efficiency of viral replication and the pathogenicity of the virus.
HCoV-229E Nucleocapsid protein connects to common cold manifestations and in some cases exacerbates chronic respiratory disorders. The N protein’s interactions with other viral proteins like the Spike protein might enhance viral entry and infectivity which could contribute to varying severity of infection. Understanding the role of the N protein in these contexts is important for developing therapeutic strategies and improving disease management for infections caused by HCoV-229E.